Novavax, Inc.
(NASDAQ : NVAX)

( )
NVAX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.96%58.190.0%$1899.37m
REGNRegeneron Pharmaceuticals, Inc. -0.26%597.002.5%$1174.48m
GILDGilead Sciences, Inc. -1.02%76.751.0%$975.82m
AMGNAmgen, Inc. 2.17%225.671.3%$660.44m
NVAXNovavax, Inc. 3.67%46.30102.0%$655.72m
VRTXVertex Pharmaceuticals, Inc. -2.61%265.691.9%$544.78m
ILMNIllumina, Inc. -1.20%354.113.5%$388.06m
BIIBBiogen, Inc. 2.36%306.721.6%$378.26m
SRNESorrento Therapeutics, Inc. 6.74%4.121.8%$269.11m
ALXNAlexion Pharmaceuticals, Inc. 1.35%115.212.0%$241.70m
SGENSeattle Genetics, Inc. -1.36%148.396.1%$223.95m
AAgilent Technologies, Inc. -0.83%90.381.6%$215.81m
BMRNBioMarin Pharmaceutical, Inc. -1.59%105.804.3%$184.97m
SRPTSarepta Therapeutics, Inc. 2.06%147.9913.9%$156.63m
INCYIncyte Corp. -0.31%93.512.5%$153.41m

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.